Abstract
In an attempt to examine whether autologous SCT provides long-term disease control in patients with intermediate and high-risk AML where a suitable donor is not available, we analyzed the outcomes of autologous SCT in patients with intermediate and high-risk AML from 1986 to 2005. No relapses occurred after 2.2 years. The overall survival curve appears to have developed a plateau after 2.2 years. In conclusion, autologous SCT in patients with AML in whom an allogeneic transplantation is not feasible appears to be a safe alternative and a plateau in the survival curve indicates cure in a small proportion of patients.
Original language | English (US) |
---|---|
Pages (from-to) | 1253-1257 |
Number of pages | 5 |
Journal | Leukemia Research |
Volume | 31 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2007 |
Keywords
- Acute myeloid leukemia
- Bone marrow transplantation
- Stem cell transplantation
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research